Stem-Cell Treatments Become More Available, and Face More Scrutiny
By Melinda Beck,
Wall Street Journal
| 08. 29. 2016
In two days of hearings next month, the U.S. Food and Drug Administration will consider if clinics offering stem-cell treatments should be more closely regulated.
Stem-cell treatments aren’t approved by the FDA and not long ago, Americans had to travel to Mexico, China or elsewhere to receive them. Now, with the regulatory environment murky, clinics offering them are spreading rapidly across the U.S. A recent report in the journal Cell Stem Cell counted 570 clinics advertising stem-cell therapies directly to consumers. Many claim to treat a long list of disorders, from arthritis to Alzheimer’s disease, even though the stem-cell treatment for many of the conditions hasn’t yet been tested on humans. Treatment typically costs thousands of dollars.
Critics, including many top stem-cell scientists, say the clinics are peddling 21st century snake oil and want the FDA to crack down. Clinic operators say they don’t need FDA approval because they are practicing medicine, not creating new drugs. Some patients say they have been helped and that the government shouldn’t regulate what they do with their own cells.
Stem cells, found in...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
